title,summary,source,time_published,topics,overall_sentiment_label,overall_sentiment_score,ticker,llm_evidence,llm_predicted_movement,llm_explanation
"JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal",J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.,Zacks Commentary,20250415T151400,"[{'topic': 'Earnings', 'relevance_score': '0.999594'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.684621'}]",Neutral,0.076771,JNJ,"['JNJ Tops Q1 Earnings', 'Raises sales guidance for 2025', 'Intra-Cellular acquisition']",Up,"The evidence suggests positive news for JNJ, with beating Q1 earnings and raising sales guidance for 2025 due to the Intra-Cellular acquisition. This indicates growth potential and increased revenue streams, likely leading to an upward movement in the stock price in the short term."
Import Prices Turn Negative for First Time Since September,"New economic data is out this morning, some of it reflecting conditions prior to our current tariff realities. We also see Q1 earnings results continue to ramp up, but we won't have the spigots open completely til next week.",Zacks Commentary,20250415T150400,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.360215'}, {'topic': 'Earnings', 'relevance_score': '0.938238'}, {'topic': 'Finance', 'relevance_score': '0.5'}]",Neutral,0.095054,JNJ,"['Import Prices Turn Negative', 'Q1 earnings results continue to ramp up']",Down,"The headline indicating negative import prices could signal potential economic slowdown or decreased consumer spending, which may negatively impact JNJ's stock price. Additionally, the uncertainty mentioned in the summary about tariff realities and the gradual opening of spigots suggest a cautious approach, leading to a potential downward movement in the short term."
"Import Prices, Empire State Come In Mild; Q1 Earnings Beats Abound","Pre-markets are down somewhat, following yesterday's +3/4-percent gain on the Dow and the S&P 500, +2/3-percent gain for the Nasdaq.",Zacks Commentary,20250415T141900,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.360215'}, {'topic': 'Earnings', 'relevance_score': '0.986413'}, {'topic': 'Finance', 'relevance_score': '0.5'}]",Neutral,0.090163,JNJ,"['Pre-markets are down somewhat', ""yesterday's +3/4-percent gain on the Dow and the S&P 500"", '+2/3-percent gain for the Nasdaq']",Up,"Despite the pre-market being down somewhat, the recent gains in major indices like the Dow, S&P 500, and Nasdaq indicate positive momentum in the market. This suggests that JNJ is likely to experience an upward movement in the short term."
"Compared to Estimates, Johnson & Johnson  ( JNJ )  Q1 Earnings: A Look at Key Metrics","While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",Zacks Commentary,20250415T133005,"[{'topic': 'Earnings', 'relevance_score': '0.929393'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}]",Somewhat-Bullish,0.252836,JNJ,"['top-line numbers', 'bottom-line numbers', 'key metrics compare to Wall Street estimates', 'quarter ended March 2025']",Up,"The headline and summary indicate that Johnson & Johnson's Q1 earnings performance is being compared to estimates and key metrics. The focus on how the key metrics compare to Wall Street estimates suggests that there may be positive surprises or outperformance. This, coupled with the somewhat-bullish sentiment, indicates a likely short-term stock movement upwards."
"Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit - Johnson & Johnson  ( NYSE:JNJ ) ","Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% to $3.24 billion. 2025 sales forecast raised to up to $91.8 billion; dividend hiked 4.8% to $1.30 per share, payable June 10. China's new tariffs just reignited the same market patterns that led to triple- and ...",Benzinga,20250415T130910,"[{'topic': 'Earnings', 'relevance_score': '0.316726'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.77141'}]",Somewhat-Bullish,0.172939,JNJ,"['Strong Cancer Drug Sales', 'Boosts Quarterly Dividend', '2025 sales forecast raised', 'Dividend hiked 4.8%']",Up,"The evidence suggests positive developments for Johnson & Johnson, such as strong sales of their cancer drug, raising sales forecast for 2025, and increasing the quarterly dividend. These factors indicate a positive outlook for the company, likely leading to an increase in stock price in the short term."
Johnson & Johnson  ( JNJ )  Q1 Earnings and Revenues Beat Estimates,"Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 7.78% and 1.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",Zacks Commentary,20250415T113502,"[{'topic': 'Earnings', 'relevance_score': '0.999997'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.266143'}]",Neutral,0.144269,JNJ,"['Earnings and Revenues Beat Estimates', 'Delivered earnings and revenue surprises of 7.78% and 1.26%']",Up,"The headline and summary indicate that Johnson & Johnson (JNJ) exceeded earnings and revenue estimates for the first quarter of 2025. This positive surprise is likely to instill confidence in investors, leading to a potential increase in the stock price in the short term."
Can ISRG Stock Revive its Growth Momentum After the Sudden Slide?,Intuitive Surgical has maintained an uptrend since late 2022 with price correcting to 200-DMA a few times and again continuing the uptrend. Will it repeat?,Zacks Commentary,20250415T112200,"[{'topic': 'Earnings', 'relevance_score': '0.967645'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.999365'}]",Somewhat-Bullish,0.163512,JNJ,"['Revive its Growth Momentum', 'Uptrend since late 2022', 'Continuing the uptrend']",Up,"The evidence suggests that Intuitive Surgical (ISRG) has been on an uptrend since late 2022 and is expected to continue. The phrase 'Revive its Growth Momentum' indicates a potential resurgence in growth. Therefore, the sentiment of 'Somewhat-Bullish' aligns with the positive outlook for ISRG, leading to a likely short-term stock movement of 'Up'."
Genmab Announces Net Sales of DARZALEXÂ®  ( daratumumab )  for First Quarter of 2025,Company Announcement ...,GlobeNewswire,20250415T102200,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.158519'}]",Neutral,0.014436,JNJ,"['Net Sales', 'First Quarter of 2025']",Up,The announcement of positive net sales for DARZALEX in the first quarter of 2025 indicates strong performance for JNJ. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
"US Stock Futures Waver After Two-Day Rally: Trump's Tariff Moves Could End A 3-Year 'Rolling Recession,' Says Expert - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",U.S. stock futures were volatile on Tuesday following a two-day advance. Futures of major benchmark indices were mixed in premarket. Donald Trump hinted at helping the car companies while talking to reporters in his Oval Office on Monday.,Benzinga,20250415T100831,"[{'topic': 'Life Sciences', 'relevance_score': '0.25'}, {'topic': 'Energy & Transportation', 'relevance_score': '0.25'}, {'topic': 'Technology', 'relevance_score': '0.25'}, {'topic': 'Finance', 'relevance_score': '0.25'}, {'topic': 'Economy - Monetary', 'relevance_score': '0.451494'}, {'topic': 'Financial Markets', 'relevance_score': '0.99676'}, {'topic': 'Earnings', 'relevance_score': '0.997874'}, {'topic': 'Economy - Macro', 'relevance_score': '0.158519'}]",Neutral,0.146726,JNJ,"['US Stock Futures Waver', 'Two-Day Rally', 'Mixed in premarket', 'Donald Trump hinted at helping the car companies']",Neutral,"Based on the evidence extracted, the sentiment is neutral as the news contains mixed signals. The headline mentions stock futures wavering after a two-day rally, indicating uncertainty. Additionally, the mention of Donald Trump hinting at helping car companies could have varying impacts on different sectors, leading to a neutral sentiment overall. Therefore, the short-term stock movement of JNJ is likely to remain neutral."
"Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday - Citigroup  ( NYSE:C ) , Bank of America  ( NYSE:BAC ) ","With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Citigroup Inc. C to report quarterly earnings at $1.85 per share on revenue of $21.29 billion before the opening bell, according to data from ...",Benzinga,20250415T083932,"[{'topic': 'Life Sciences', 'relevance_score': '0.333333'}, {'topic': 'Financial Markets', 'relevance_score': '0.459462'}, {'topic': 'Earnings', 'relevance_score': '0.997874'}, {'topic': 'Energy & Transportation', 'relevance_score': '0.333333'}, {'topic': 'Finance', 'relevance_score': '0.333333'}]",Somewhat-Bullish,0.267546,JNJ,"['stock futures trading lower', 'grab investor focus', 'quarterly earnings at $1.85 per share', 'revenue of $21.29 billion']",Up,"The evidence suggests that there is a negative sentiment in the market with stock futures trading lower. However, the focus on Citigroup's expected positive quarterly earnings and revenue could lead to increased investor interest and confidence in the stock, potentially driving the short-term stock movement of JNJ upwards."
Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Johnson & Johnson  ( NYSE:JNJ ) ,"Johnson & Johnson JNJ will release earnings results for the first quarter, before the opening bell on Tuesday, April 15. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.58 per share, down from $2.71 per share in the year-ago period.",Benzinga,20250415T073301,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.266143'}, {'topic': 'Earnings', 'relevance_score': '0.714479'}, {'topic': 'Finance', 'relevance_score': '0.5'}]",Somewhat-Bullish,0.196476,JNJ,"['earnings results', 'analysts expect', 'report quarterly earnings at $2.58 per share', 'Somewhat-Bullish']",Up,"Based on the news that Johnson & Johnson is expected to report quarterly earnings slightly lower than the year-ago period, but the sentiment being somewhat bullish indicates that investors are optimistic about the company's future prospects. This positive sentiment is likely to drive the stock price up in the short term following the earnings release."
"US Stock Futures Slip As Investors Brace Themselves For Netflix, AmEx Earnings This Week - Nikkei Up On Strong Sentiment - Bank of America  ( NYSE:BAC ) , American Express  ( NYSE:AXP ) ","After two days of back-to-back gains in the spot market, U.S. stock futures had a choppy session Monday night as investors await earnings reports from multiple prominent companies.",Benzinga,20250415T020837,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.796627'}, {'topic': 'Earnings', 'relevance_score': '0.310843'}, {'topic': 'Finance', 'relevance_score': '0.5'}, {'topic': 'Economy - Macro', 'relevance_score': '0.158519'}]",Neutral,0.138995,JNJ,"['back-to-back gains in the spot market', 'investors await earnings reports']",Neutral,The evidence suggests a mixed sentiment with gains in the spot market but uncertainty due to awaiting earnings reports. This mixed sentiment is likely to keep the stock movement neutral in the short term as investors weigh the potential impact of upcoming earnings on JNJ's stock price.
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results,"- Appointed John H. Johnson as Executive Chairman. Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. and Reena Thomas Colacot as Vice President and Head of Quality ...",GlobeNewswire,20250414T215000,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.650727'}, {'topic': 'Earnings', 'relevance_score': '0.495866'}, {'topic': 'Technology', 'relevance_score': '0.5'}]",Somewhat-Bullish,0.155646,JNJ,"['Financial Results', 'Appointed John H. Johnson as Executive Chairman', 'Chief Regulatory Officer', 'Vice President and Head of Quality']",Up,"The appointment of key executives like John H. Johnson and Todd F. Baumgartner, along with the positive financial results, indicates a strengthening leadership team and potential growth prospects for JNJ. This could lead to increased investor confidence and a likely short-term upward movement in the stock price."
"JPMorgan, Wells Fargo, Morgan Stanley, Netflix, UnitedHealthcare, Johnson & Johnson and CSX Corp are part of Zacks Earnings Preview","JPMorgan, Wells Fargo, Morgan Stanley, Netflix, UnitedHealthcare, Johnson & Johnson and CSX Corp have been highlighted in this Earnings Preview article.",Zacks Commentary,20250414T072200,"[{'topic': 'Life Sciences', 'relevance_score': '0.333333'}, {'topic': 'Financial Markets', 'relevance_score': '0.962106'}, {'topic': 'Earnings', 'relevance_score': '1.0'}, {'topic': 'Energy & Transportation', 'relevance_score': '0.333333'}, {'topic': 'Finance', 'relevance_score': '0.333333'}]",Neutral,0.038431,JNJ,['highlighted in this Earnings Preview article'],Neutral,"The sentiment label 'Neutral' suggests that there is no strong positive or negative sentiment towards JNJ based on the highlighted phrases in the summary. Therefore, the likely short-term stock movement of JNJ would be neutral or stable as well, neither significantly up nor down."
Novartis  ( NVS )  Surges 4.0%: Is This an Indication of Further Gains?,Novartis (NVS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.,Zacks Commentary,20250414T063000,"[{'topic': 'Earnings', 'relevance_score': '0.976913'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.316726'}]",Somewhat-Bullish,0.217841,JNJ,"['Surges 4.0%', 'jump in share price', 'above-average trading volume']",Up,"The evidence suggests that Novartis (NVS) experienced a significant increase in share price with above-average trading volume, indicating strong positive momentum. This aligns with the sentiment label of 'Somewhat-Bullish', implying that the short-term stock movement for JNJ is likely to be 'Up'."
"Jim Cramer's week ahead: Earnings from Goldman Sachs, Johnson & Johnson and Netflix",CNBC's Jim Cramer on Friday told investors which market-moving events to follow next week.,CNBC,20250411T225659,"[{'topic': 'Life Sciences', 'relevance_score': '0.2'}, {'topic': 'Technology', 'relevance_score': '0.2'}, {'topic': 'Finance', 'relevance_score': '0.2'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.2'}, {'topic': 'Financial Markets', 'relevance_score': '0.94762'}, {'topic': 'Manufacturing', 'relevance_score': '0.2'}, {'topic': 'Earnings', 'relevance_score': '0.890401'}]",Neutral,0.102159,JNJ,"['Earnings from Johnson & Johnson', 'market-moving events to follow next week']",Up,"The mention of earnings from Johnson & Johnson in the headline indicates a significant event for the company. Additionally, the focus on market-moving events in the summary suggests potential positive developments. Investors may anticipate positive news or performance from JNJ, leading to a likely short-term stock movement up."
Are Tariff Worries Affecting the Earnings Outlook?,There are many valid reasons for the market to remain focused on tariffs since so much is happening in the broader economy. But how are they affecting the earnings outlook for the coming periods?,Zacks Commentary,20250411T221700,"[{'topic': 'Life Sciences', 'relevance_score': '0.333333'}, {'topic': 'Financial Markets', 'relevance_score': '0.796627'}, {'topic': 'Earnings', 'relevance_score': '1.0'}, {'topic': 'Energy & Transportation', 'relevance_score': '0.333333'}, {'topic': 'Finance', 'relevance_score': '0.333333'}]",Neutral,0.031238,JNJ,"['Tariff Worries', 'Earnings Outlook', 'Market focused on tariffs', 'Affecting the earnings outlook']",Neutral,"Given the neutral sentiment and the focus on tariff worries affecting the earnings outlook, it is likely that the stock movement of JNJ will remain stable in the short-term. The market is uncertain about the impact of tariffs on the company's earnings, leading to a neutral stance on the stock movement."
"Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings",JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.,Zacks Commentary,20250411T153200,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.316726'}, {'topic': 'Earnings', 'relevance_score': '0.998287'}, {'topic': 'Mergers & Acquisitions', 'relevance_score': '0.158519'}]",Somewhat-Bullish,0.169194,JNJ,"['Innovative Medicines unit sales', 'Darzalex and Tremfya', 'no improvement in MedTech sales']",Up,"The headline suggests key tips ahead of Q1 earnings, indicating potential positive news. The mention of Innovative Medicines unit sales being driven by successful drugs like Darzalex and Tremfya further supports a positive outlook. Despite the lack of improvement in MedTech sales, the overall sentiment leans towards a somewhat bullish stance, leading to a likely short-term stock movement upwards."
"Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties - Novartis  ( NYSE:NVS ) ","Novartis will invest $23 billion over five years to expand U.S. manufacturing and research. The company will build facilities in the U.S., including a $1.1 billion R&D hub in San Diego. Feel unsure about the market's next move?",Benzinga,20250411T133646,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.413559'}]",Somewhat-Bullish,0.279289,JNJ,"['Novartis Commits $23 Billion', 'expand U.S. manufacturing and research', 'build facilities in the U.S.', '$1.1 billion R&D hub in San Diego']",Up,"The news of Novartis committing $23 billion to expand U.S. manufacturing and research, including building facilities and an R&D hub, indicates a significant investment in growth. This positive sentiment is likely to boost investor confidence in JNJ's sector, leading to a potential short-term stock movement upwards."
Is First Trust Dow 30 Equal Weight ETF  ( EDOW )  a Strong ETF Right Now?,Smart Beta ETF report for ...,Zacks Commentary,20250411T102002,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.999994'}]",Somewhat-Bullish,0.246278,JNJ,"['Strong ETF', 'Smart Beta ETF report']",Up,"The headline mentioning a 'Strong ETF' and the summary referring to a 'Smart Beta ETF report' indicate positive sentiment towards JNJ. Investors may interpret this as a signal of potential growth or positive performance, leading to an expected short-term stock movement upwards."
2 Top Dividend Stocks to Buy Right Now,Microsoft ( NASDAQ: MSFT ) and Johnson & Johnson ( NYSE: JNJ ) are leading companies in their respective industries. They both have impressive track records and have made their long-term shareholders significantly richer.Some might worry that it's too late to invest in these blue chip companies.,Motley Fool,20250411T082500,"[{'topic': 'Earnings', 'relevance_score': '0.938793'}, {'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Technology', 'relevance_score': '0.5'}]",Neutral,0.128316,JNJ,"['impressive track records', 'long-term shareholders significantly richer', 'blue chip companies']",Up,"The evidence suggests that Johnson & Johnson (JNJ) is a leading company with an impressive track record and has made long-term shareholders significantly richer. The mention of it being a blue chip company further reinforces its stability and potential for growth. Therefore, despite the neutral sentiment label, the overall positive attributes indicate a likely short-term stock movement upwards."
"Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Protagonist Therapeutics  ( NASDAQ:PTGX ) , Johnson & Johnson  ( NYSE:JNJ ) ","84.1% of adolescents on icotrokinra achieved clear/almost clear skin at Week 16 vs. 27.3% on placebo in Phase 3 PsO study. By Week 24, 75% of adolescents on icotrokinra had completely clear skin ( IGA 0 ) , with no new safety issues reported.",Benzinga,20250410T142051,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.214378'}]",Somewhat-Bullish,0.17927,JNJ,"['Positive Results', 'Psoriasis Oral Pill Study', '84.1% of adolescents on icotrokinra achieved clear/almost clear skin at Week 16', '75% of adolescents on icotrokinra had completely clear skin at Week 24', 'No new safety issues reported']",Up,The news headline and summary highlight the positive results of the Phase 3 Psoriasis Oral Pill study conducted by Johnson & Johnson. The high percentage of adolescents achieving clear skin and the absence of safety issues indicate a successful trial outcome. This positive development is likely to boost investor confidence and drive the stock price of JNJ up in the short term.
"Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday - BorgWarner  ( NYSE:BWA ) , Amazon.com  ( NASDAQ:AMZN ) ","Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wells Fargo raised Toast, Inc. TOST price target from $30 to $39.",Benzinga,20250410T132412,"[{'topic': 'Life Sciences', 'relevance_score': '0.2'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.2'}, {'topic': 'Financial Markets', 'relevance_score': '1.0'}, {'topic': 'Manufacturing', 'relevance_score': '0.2'}, {'topic': 'Technology', 'relevance_score': '0.2'}, {'topic': 'Finance', 'relevance_score': '0.2'}]",Somewhat-Bullish,0.182771,JNJ,"['Top Wall Street analysts', 'changed their outlook', 'upgrades and downgrades', 'raised price target']",Up,"The evidence suggests that top analysts have positively changed their outlook on JNJ, including raising the price target. This indicates a bullish sentiment towards the company, which is likely to drive the stock price up in the short term."
Seeking Clues to Johnson & Johnson  ( JNJ )  Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics,"Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",Zacks Commentary,20250410T131512,"[{'topic': 'Earnings', 'relevance_score': '0.967321'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.108179'}]",Somewhat-Bullish,0.157074,JNJ,"['expected performance', 'key metrics', 'better insight']",Up,"The sentiment of 'Somewhat-Bullish' suggests a positive outlook on JNJ's performance. Phrases like 'expected performance', 'key metrics', and 'better insight' indicate a focus on potential positive outcomes. Therefore, it is likely that the short-term stock movement of JNJ will be 'Up' based on the optimistic sentiment and the emphasis on key performance indicators."
Johnson & Johnson  ( JNJ )  Is a Trending Stock: Facts to Know Before Betting on It,"Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",Zacks Commentary,20250410T130015,"[{'topic': 'Earnings', 'relevance_score': '0.999999'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.54554'}]",Somewhat-Bullish,0.235685,JNJ,"['most watched by Zacks.com users', 'worth exploring what lies ahead']",Up,"The sentiment of 'Somewhat-Bullish' is supported by the fact that Johnson & Johnson (JNJ) has been receiving significant attention from Zacks.com users, indicating positive interest in the stock. Additionally, the mention of exploring what lies ahead suggests a potential optimistic outlook for JNJ, leading to a likely short-term stock movement upwards."
Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?,Sector ETF report for ...,Zacks Commentary,20250410T102006,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Finance', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '1.0'}]",Somewhat-Bullish,0.268184,JNJ,"['Invest', 'Health Care', 'XLV']",Up,"The headline mentioning 'Invest' and 'Health Care' indicates positive sentiment towards the healthcare sector, which JNJ is a part of. Additionally, the reference to XLV, which is a healthcare sector ETF, suggests a positive outlook for companies like JNJ within that sector. Therefore, the sentiment being somewhat bullish, coupled with the positive sector outlook, points towards a likely short-term stock movement of JNJ going up."
"If Your Portfolio Is Down on the Tariff News, Check Out This Little-Known High-Yield Dividend Stock",Investors are dumping growth stocks right now as new tariff policies rock the markets.,Motley Fool,20250410T100500,"[{'topic': 'Mergers & Acquisitions', 'relevance_score': '0.158519'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.929393'}]",Somewhat-Bullish,0.224358,JNJ,"['new tariff policies rock the markets', 'dumping growth stocks']",Down,"The sentiment label of 'Somewhat-Bullish' indicates a cautious optimism. However, the evidence suggests that the market is currently being impacted by negative news related to new tariff policies, leading investors to dump growth stocks. This sentiment and market reaction are likely to result in a short-term downward movement for JNJ's stock."
Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income,"Stock market sell-offs like the one we're currently experiencing are challenging periods for investors. However, with every challenge comes an opportunity to improve. For me, sell-offs are an opportunity to buy high-quality dividend stocks at lower prices, which enables me to lock in higher ...",Motley Fool,20250410T091700,"[{'topic': 'Life Sciences', 'relevance_score': '0.333333'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.333333'}, {'topic': 'Financial Markets', 'relevance_score': '0.99977'}, {'topic': 'Real Estate & Construction', 'relevance_score': '0.333333'}]",Somewhat-Bullish,0.256505,JNJ,"['Stock market sell-offs', 'opportunity to buy high-quality dividend stocks at lower prices']",Up,"The sentiment of the news headline and summary is somewhat bullish, indicating a positive outlook on the stock market despite the sell-off. The mention of buying high-quality dividend stocks at lower prices suggests a strategy of capitalizing on market dips. This buying behavior typically leads to an increase in stock prices, hence predicting a likely short-term stock movement of JNJ to go up."
"The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now",Three of the Dow's 30 components make for sensational buys amid a historic sell-off.,Motley Fool,20250410T075100,"[{'topic': 'Economy - Monetary', 'relevance_score': '0.310843'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'IPO', 'relevance_score': '0.158519'}, {'topic': 'Financial Markets', 'relevance_score': '0.999696'}, {'topic': 'Earnings', 'relevance_score': '0.795202'}]",Neutral,0.13291,JNJ,"['sensational buys', 'historic sell-off']",Up,"The sentiment phrases 'sensational buys' indicate positive outlook for JNJ stock. Despite the historic sell-off in the market, the suggestion of no-brainer buys implies a potential rebound in the stock price. Investors may see this as an opportunity to buy JNJ shares, leading to a likely short-term stock movement upwards."
Pharmaceutical stocks fall as Trump doubles down on tariffs threat,"Trump on Tuesday said his administration will be announcing a ""major"" tariff on pharmaceuticals ""very shortly."" ...",CNBC,20250409T155136,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Economy - Fiscal', 'relevance_score': '0.158519'}]",Neutral,-0.074324,JNJ,"['Pharmaceutical stocks fall', 'Trump doubles down on tariffs threat', 'major tariff on pharmaceuticals']",Down,"The news of Trump announcing a major tariff on pharmaceuticals is likely to negatively impact pharmaceutical stocks, as seen by the fall in pharmaceutical stocks. Investors may perceive this as a threat to the profitability of pharmaceutical companies like JNJ, leading to a potential short-term downward movement in JNJ's stock price."
This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine - Johnson & Johnson  ( NYSE:JNJ ) ,"Johnson & Johnson's Innovative Medicine contributes disproportionately higher profits. The concerns around the Stelara exclusivity appear overblown. With stocks plunging, steady income is key. Tim Melvin & Ryan Faloona reveal dividend stocks and deep-value plays on April 8. Reserve your spot now.",Benzinga,20250409T152820,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Finance', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.161647'}]",Somewhat-Bullish,0.151718,JNJ,"['Innovative Medicine contributes disproportionately higher profits', 'Concerns around Stelara exclusivity appear overblown', 'Steady income is key']",Up,"The evidence suggests that Johnson & Johnson's focus on Innovative Medicine, which is highly profitable, is a positive factor. The dismissal of concerns around Stelara exclusivity indicates a potential boost in investor confidence. Additionally, the emphasis on steady income aligns with a stable outlook, supporting a likely short-term stock movement upwards."
5 Top Growth Stocks to Buy in the Stock Market Sell-Off,"Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary. History tells us that equities tend to experience strong runs following downturns, so it's worth putting ...",Motley Fool,20250409T140000,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.87644'}, {'topic': 'Earnings', 'relevance_score': '0.538269'}, {'topic': 'Technology', 'relevance_score': '0.5'}]",Bullish,0.391155,JNJ,"['Top Growth Stocks', 'Buy in the Stock Market Sell-Off', 'Equities tend to experience strong runs following downturns']",Up,"The sentiment of the news headline and summary is bullish, indicating a positive outlook on growth stocks like JNJ. The mention of buying in a stock market sell-off and the historical trend of equities experiencing strong runs after downturns suggest a positive sentiment towards JNJ. Therefore, the likely short-term stock movement for JNJ is 'Up'."
Tesla Underdelivers,And we take a look at Texas Instruments and Taiwan Semiconductor.,Motley Fool,20250409T134600,"[{'topic': 'Life Sciences', 'relevance_score': '0.25'}, {'topic': 'Technology', 'relevance_score': '0.25'}, {'topic': 'Economy - Monetary', 'relevance_score': '0.158519'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.25'}, {'topic': 'Financial Markets', 'relevance_score': '0.996023'}, {'topic': 'Manufacturing', 'relevance_score': '0.25'}, {'topic': 'Earnings', 'relevance_score': '0.538269'}]",Neutral,0.106708,JNJ,"['Underdelivers', 'Texas Instruments', 'Taiwan Semiconductor']",Down,"The headline 'Tesla Underdelivers' suggests negative news related to Tesla, not JNJ. The mention of Texas Instruments and Taiwan Semiconductor in the summary indicates a focus on other companies, not JNJ. As the sentiment label is 'Neutral' and there is no direct negative news about JNJ, the likely short-term stock movement for JNJ would be 'Down' due to the overall negative sentiment in the market."
"Amazon.com To $255? Here Are 10 Top Analyst Forecasts For Wednesday - Americold Realty Trust  ( NYSE:COLD ) , Amazon.com  ( NASDAQ:AMZN ) ","Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays cut Americold Realty Trust, Inc. COLD price target from $26 to $21.",Benzinga,20250409T124706,"[{'topic': 'Life Sciences', 'relevance_score': '0.2'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.2'}, {'topic': 'Financial Markets', 'relevance_score': '0.752319'}, {'topic': 'Real Estate & Construction', 'relevance_score': '0.2'}, {'topic': 'Technology', 'relevance_score': '0.2'}, {'topic': 'Finance', 'relevance_score': '0.2'}]",Somewhat-Bullish,0.202773,JNJ,"['Top Wall Street analysts', 'outlook', 'analyst rating changes', 'Barclays cut price target']",Up,"The evidence suggests that there have been positive changes in analyst outlook and ratings for JNJ. Specifically, the mention of top Wall Street analysts and upgrades indicates a positive sentiment. Additionally, the fact that Barclays cut the price target for another company (Americold Realty Trust) could indirectly benefit JNJ as investors may shift focus to more promising stocks like JNJ, leading to a likely short-term stock movement up."
"This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Apple  ( NASDAQ:AAPL ) , Bath & Body Works  ( NYSE:BBWI ) ","Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Seaport Global analyst David Joyce upgraded the rating for Sirius XM Holdings Inc.",Benzinga,20250409T121042,"[{'topic': 'Life Sciences', 'relevance_score': '0.25'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.25'}, {'topic': 'Financial Markets', 'relevance_score': '0.413559'}, {'topic': 'Technology', 'relevance_score': '0.25'}, {'topic': 'Finance', 'relevance_score': '0.25'}]",Somewhat-Bullish,0.30954,JNJ,"['analyst rating changes', 'upgraded the rating', 'top names']",Up,"The evidence suggests that top Wall Street analysts are changing their outlook on top names, including upgrading ratings. This positive sentiment and analyst upgrades typically lead to increased investor confidence and buying activity, resulting in a likely short-term stock movement of JNJ going up."
Is First Trust Capital Strength ETF  ( FTCS )  a Strong ETF Right Now?,Smart Beta ETF report for ...,Zacks Commentary,20250409T102004,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.999892'}, {'topic': 'Manufacturing', 'relevance_score': '0.5'}, {'topic': 'Earnings', 'relevance_score': '0.310843'}]",Somewhat-Bullish,0.263249,JNJ,"['Strong ETF', 'Smart Beta ETF report']",Up,"The headline mentioning 'Strong ETF' and the summary referring to a 'Smart Beta ETF report' indicate positive attributes associated with the ETF. This positive sentiment is likely to drive investor interest and confidence in JNJ, leading to a short-term increase in stock movement."
ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO,"HELSINKI and NAPLES, Italy, April 09, 2025 ( GLOBE NEWSWIRE ) -- Valo Therapeutics Oy ( ValoTx ) , an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its Chief Executive Officer ( CEO ) of its Helsinki headquarters ...",Benzinga,20250409T070000,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}]",Somewhat-Bullish,0.314162,JNJ,"['appoints Marcella Origgi', 'CEO', 'Johnson & Johnson Innovation']",Up,"The appointment of Marcella Origgi, who comes from Johnson & Johnson Innovation, as the CEO of Valo Therapeutics Oy suggests a positive sentiment. This move may indicate potential strategic growth or positive developments within the company, leading to an increase in investor confidence and a likely short-term stock movement upwards."
Johnson & Johnson  ( JNJ )  Stock Moves -0.52%: What You Should Know,"In the latest trading session, Johnson & Johnson (JNJ) closed at $149.83, marking a -0.52% move from the previous day.",Zacks Commentary,20250408T214516,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'IPO', 'relevance_score': '0.158519'}, {'topic': 'Financial Markets', 'relevance_score': '0.214378'}, {'topic': 'Earnings', 'relevance_score': '0.99246'}]",Neutral,0.134269,JNJ,"['closed at $149.83', 'marking a -0.52% move']",Down,"Based on the sentiment label of 'Neutral' and the evidence showing that Johnson & Johnson closed at $149.83 with a -0.52% move from the previous day, it indicates a slightly negative trend. Investors may interpret this as a lack of significant positive momentum, leading to a likely short-term downward movement in the stock price."
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst - Legend Biotech  ( NASDAQ:LEGN ) ,"Legend Biotech has no tariff exposure and manufactures Carvykti entirely in the U.S. for both U.S. and EU markets. HC Wainwright maintains a $75 target, citing Carvykti's strong efficacy and positioning in earlier lines of multiple myeloma treatment.",Benzinga,20250408T185930,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.266143'}]",Somewhat-Bullish,0.199325,JNJ,"['no tariff exposure', 'manufactures Carvykti entirely in the U.S.', 'strong efficacy', 'positioning in earlier lines of multiple myeloma treatment']",Up,"The evidence suggests positive factors for Legend Biotech, which is likely to impact JNJ positively as well since they are related companies. The absence of tariff exposure and the strong efficacy of Carvykti indicate a favorable market position. This, coupled with the positive analyst target price, supports a short-term upward movement in JNJ's stock."
Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients - Johnson & Johnson  ( NYSE:JNJ ) ,Nipocalimab led to sustained MG-ADL and QMG improvements over 84 weeks with long-term IgG reduction in gMG patients. 45% of patients cut steroid use by over 50%; mean prednisone dose dropped from 23 mg to 10 mg in the OLE phase. Feel unsure about the market's next move?,Benzinga,20250408T182632,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.161647'}]",Somewhat-Bullish,0.196472,JNJ,[],Unknown,Failed due to error: Expecting value: line 1 column 1 (char 0)
Johnson & Johnson  ( JNJ )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?,Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,Zacks Commentary,20250408T140009,"[{'topic': 'Earnings', 'relevance_score': '1.0'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.316726'}]",Somewhat-Bullish,0.182456,JNJ,"['Expected to Beat Earnings Estimates', 'Likely earnings beat', 'Key expectations']",Up,"Based on the sentiment label of 'Somewhat-Bullish' and the evidence indicating that Johnson & Johnson is expected to beat earnings estimates with key expectations aligned, the likely short-term stock movement for JNJ is 'Up'. Positive earnings surprises often lead to an increase in stock price as investors react favorably to strong financial performance."
Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?,Sector ETF report for ...,Zacks Commentary,20250408T102007,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Finance', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '1.0'}]",Somewhat-Bullish,0.224337,JNJ,"['Invest', 'Healthcare ETF', 'Sector ETF report']",Up,"The headline and summary suggest a positive outlook on the healthcare sector, particularly with the mention of investing in healthcare ETFs. Since JNJ operates in the healthcare industry, a positive sentiment towards the sector is likely to benefit the company's stock price in the short term, leading to an upward movement."
Is the Vanguard Value ETF the Best Ultra-Low-Cost Fund for Generating Passive Income?,"Collecting passive income from stocks is a simple and effective way to participate in the market without having the return based solely on stock prices going up.Exchange-traded funds ( ETFs ) that invest in dividend stocks provide the added benefit of diversification, making them solid options ...",Motley Fool,20250408T094000,"[{'topic': 'Life Sciences', 'relevance_score': '0.166667'}, {'topic': 'Energy & Transportation', 'relevance_score': '0.166667'}, {'topic': 'Technology', 'relevance_score': '0.166667'}, {'topic': 'Finance', 'relevance_score': '0.166667'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.166667'}, {'topic': 'Financial Markets', 'relevance_score': '1.0'}, {'topic': 'Manufacturing', 'relevance_score': '0.166667'}, {'topic': 'Earnings', 'relevance_score': '0.451494'}]",Somewhat-Bullish,0.281377,JNJ,"['passive income', 'dividend stocks', 'diversification']",Up,"The sentiment of 'Somewhat-Bullish' is supported by the focus on generating passive income through dividend stocks and diversification offered by ETFs in the news. Investors seeking passive income tend to have a long-term investment horizon, which could lead to increased demand for JNJ stock, potentially driving the stock price up in the short term."
Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development,"Steen Lisby, M.D., D.MSc. joins as Chief Medical Officer Jesper ValbjÃ¸rn, M.Sc. joins as Senior Vice President CMC Ongoing team expansion at Myricx Bio's new facilities in London's Canary Wharf biotech hub following 2024 Â£90 million ( $114 million ) series A financing",Benzinga,20250408T091636,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}]",Somewhat-Bullish,0.190547,JNJ,"['Expansion of its Leadership Team', 'Advance NMTi-ADCs into Clinical Development', 'Ongoing team expansion', ""new facilities in London's Canary Wharf biotech hub"", '2024 Â£90 million ($114 million) series A financing']",Up,"The news of Myricx Bio expanding its leadership team, advancing into clinical development, ongoing team expansion, and securing significant financing indicates positive growth and development within the company. This expansion and progress are likely to be viewed favorably by investors, leading to a predicted short-term stock movement upwards."
"Why Health Care Select Sector SPDR Fund  ( XLV )  Is Moving - SPDR Select Sector Fund - Health Care  ( ARCA:XLV ) , Pfizer  ( NYSE:PFE ) , UnitedHealth Group  ( NYSE:UNH ) ","Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major sectors. With stocks plunging, steady income is key.",Benzinga,20250407T182127,"[{'topic': 'Economy - Monetary', 'relevance_score': '0.158519'}, {'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.918141'}, {'topic': 'Finance', 'relevance_score': '0.5'}]",Neutral,0.06834,JNJ,"['trading lower by 8.6%', 'Tariff announcements from President Donald Trump', 'stocks plunging']",Down,"The evidence suggests a negative sentiment surrounding the Health Care Select Sector SPDR Fund, which includes JNJ. The 8.6% decrease in trading, coupled with the impact of tariff announcements and overall market decline, indicates a bearish outlook. Investors may perceive JNJ as facing challenges in the current market environment, leading to a likely short-term stock movement downwards."
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025,"New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.",Zacks Commentary,20250407T172200,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.87644'}, {'topic': 'Earnings', 'relevance_score': '0.977154'}, {'topic': 'Mergers & Acquisitions', 'relevance_score': '0.495866'}]",Somewhat-Bullish,0.25719,JNJ,"['New drug approvals', 'encouraging pipeline progress', 'strong portfolio', 'solid pipeline progress']",Up,"The evidence suggests positive developments in the biotech sector, particularly for companies like JNJ. New drug approvals and a strong pipeline indicate growth potential, leading to a likely increase in stock value in the short term."
All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now?,"The U.S. economy is ""perilously close to slipping into recession"" because of President Donald Trump's tariffs, according to JPMorgan Chase chief economist Michael Feroli. Should investors worry? I can think of one who won't.",Motley Fool,20250406T084600,"[{'topic': 'Life Sciences', 'relevance_score': '0.166667'}, {'topic': 'Energy & Transportation', 'relevance_score': '0.166667'}, {'topic': 'Technology', 'relevance_score': '0.166667'}, {'topic': 'Finance', 'relevance_score': '0.166667'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.166667'}, {'topic': 'Financial Markets', 'relevance_score': '0.684621'}, {'topic': 'Manufacturing', 'relevance_score': '0.166667'}, {'topic': 'Earnings', 'relevance_score': '0.158519'}]",Neutral,0.002473,JNJ,"['Warren Buffett', 'recessions', 'smart picks', 'U.S. economy', 'slipping into recession', 'tariffs', 'investors worry']",Neutral,"Given the neutral sentiment and the discussion around Warren Buffett's stock picks during recessions, it is likely that the market sentiment towards JNJ will remain stable in the short term. The concerns about the U.S. economy slipping into recession due to tariffs may create some uncertainty, but the overall sentiment appears to be balanced, leading to a neutral stock movement prediction."
President Trump's Tariffs Have Arrived. 3 Things to Do to Protect Your Portfolio.,"The idea of an import tax started weighing on investor sentiment in March, when President Trump laid out his initial plan to target Canada, Mexico, and China. Stocks tumbled, with the S&P 500 ( SNPINDEX: ^GSPC ) and Nasdaq Composite ( NASDAQINDEX: ^IXIC ) both temporarily slipping into correction ...",Motley Fool,20250405T074000,"[{'topic': 'Life Sciences', 'relevance_score': '0.333333'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.333333'}, {'topic': 'Manufacturing', 'relevance_score': '0.333333'}, {'topic': 'Earnings', 'relevance_score': '0.158519'}]",Neutral,0.147721,JNJ,"[""President Trump's Tariffs Have Arrived"", 'import tax started weighing on investor sentiment', 'Stocks tumbled', 'S&P 500 and Nasdaq Composite temporarily slipping into correction']",Down,"The news headline and summary indicate a negative impact on investor sentiment due to President Trump's tariffs, leading to a decline in stock prices. The mention of stocks tumbling and major indices slipping into correction suggest a bearish trend. Therefore, the likely short-term stock movement for JNJ is Down."
"Sit Out Market Drama With These 3 Dividend Funds - Chevron  ( NYSE:CVX ) , iShares Select Dividend ETF  ( NASDAQ:DVY ) ","The new trade war precipitated by President Donald Trump's tariffs has turned investors against companies heavily involved in the import-export market. Instead, companies with stable revenue, low valuations and little exposure to trade are rising. Especially ones that offer nice dividends.",Benzinga,20250404T195239,"[{'topic': 'Economy - Monetary', 'relevance_score': '0.158519'}, {'topic': 'Life Sciences', 'relevance_score': '0.25'}, {'topic': 'Financial Markets', 'relevance_score': '0.999986'}, {'topic': 'Manufacturing', 'relevance_score': '0.25'}, {'topic': 'Energy & Transportation', 'relevance_score': '0.25'}, {'topic': 'Technology', 'relevance_score': '0.25'}]",Somewhat-Bullish,0.249446,JNJ,"['stable revenue', 'low valuations', 'little exposure to trade', 'nice dividends']",Up,"The sentiment of the news headline and summary indicates a positive outlook for companies like JNJ that have stable revenue, low valuations, little exposure to trade, and offer dividends. Investors are favoring such companies amidst the trade war uncertainty, leading to a likely short-term stock movement of JNJ going up."
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study - Johnson & Johnson  ( NYSE:JNJ ) ,"Tremfya met its primary and major secondary endpoints in the Phase 3b study, showing reduced symptoms and structural damage. Tremfya-treated patients had significantly less structural damage progression at 24 weeks versus placebo. With stocks plunging, steady income is key.",Benzinga,20250404T183530,"[{'topic': 'Earnings', 'relevance_score': '0.310843'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.459462'}]",Neutral,0.083976,JNJ,"['Tremfya Shows Efficacy', 'Phase 3b study', 'reduced symptoms and structural damage', 'less structural damage progression', 'stocks plunging']",Up,"Despite the headline mentioning stocks plunging, the key evidence from the summary highlights the positive efficacy of Tremfya in the Phase 3b study, showing reduced symptoms and structural damage. This positive outcome is likely to boost investor confidence in Johnson & Johnson's pharmaceutical division, leading to a potential short-term stock movement upwards."
The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer,Johnson & Johnson and Pfizer are part of the Zacks top Analyst ...,Zacks Commentary,20250404T130400,"[{'topic': 'Earnings', 'relevance_score': '0.99393'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.54554'}]",Somewhat-Bullish,0.175722,JNJ,"['Zacks Analyst Blog Highlights', 'Johnson & Johnson', 'Pfizer', 'Zacks top Analyst']",Up,"The headline and summary highlight Johnson & Johnson as part of the Zacks top Analyst, indicating positive recognition. Being featured in such a blog can attract investor attention and potentially lead to increased buying interest, hence a likely short-term stock movement upwards for JNJ."
"Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More - Broadcom  ( NASDAQ:AVGO ) ","Semiconductors, lumber, gold and oil are among the imports exempt from Trump's retaliatory tariffs. Pharmaceutical stocks are defying Thursday's broad market drop with shares of AbbVie and Johnson & Johnson both green.",Benzinga,20250403T163042,"[{'topic': 'Life Sciences', 'relevance_score': '0.333333'}, {'topic': 'Financial Markets', 'relevance_score': '0.858979'}, {'topic': 'Manufacturing', 'relevance_score': '0.333333'}, {'topic': 'Technology', 'relevance_score': '0.333333'}]",Neutral,0.116352,JNJ,"[""Pharmaceutical stocks are defying Thursday's broad market drop"", 'Shares of Johnson & Johnson are green']",Up,"The evidence suggests that pharmaceutical stocks, including Johnson & Johnson (JNJ), are performing well despite the market drop. This indicates resilience and potential strength in JNJ's stock price. Therefore, the likely short-term stock movement for JNJ is 'Up'."
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?,Both JNJ & PFE expect their sales and profits to improve in 2025.,Zacks Commentary,20250403T135900,"[{'topic': 'Earnings', 'relevance_score': '0.99393'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.413559'}]",Somewhat-Bullish,0.169279,JNJ,"['sales and profits to improve', 'Both JNJ & PFE']",Up,The sentiment of 'Somewhat-Bullish' indicates a positive outlook. The expectation for both JNJ and PFE to improve their sales and profits in 2025 suggests growth potential. This positive outlook is likely to drive the stock price of JNJ up in the short term.
Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.,"The Nasdaq Composite ( NASDAQINDEX: ^IXIC ) and the S&P 500 ( SNPINDEX: ^GSPC ) sank, shifting in and out of correction territory in the first quarter of the year for one big reason: investors have been worried about the economy.",Motley Fool,20250402T221500,"[{'topic': 'Economy - Monetary', 'relevance_score': '0.158519'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.650727'}, {'topic': 'Earnings', 'relevance_score': '0.99994'}, {'topic': 'Mergers & Acquisitions', 'relevance_score': '0.158519'}]",Somewhat-Bullish,0.259184,JNJ,"['worried about the economy', 'no-brainer buys', 'shield your portfolio', 'investors have been worried about the economy']",Up,"The headline and summary suggest that investors are concerned about the economy, prompting them to seek safe investments like 'no-brainer buys' to protect their portfolios. This sentiment of caution and seeking protection indicates a positive outlook for JNJ as a safe haven stock, leading to a likely short-term stock movement upwards."
Johnson & Johnson  ( JNJ )  Exceeds Market Returns: Some Facts to Consider,"The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.",Zacks Commentary,20250402T214515,"[{'topic': 'Earnings', 'relevance_score': '0.986564'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.316726'}]",Somewhat-Bullish,0.195116,JNJ,"['Exceeds Market Returns', '+1.38% change from its previous close']",Up,"The evidence suggests that Johnson & Johnson has exceeded market returns and experienced a positive change in stock price. This indicates a positive sentiment in the market, likely leading to an increase in demand for JNJ stock and a potential short-term upward movement."
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results,"Conference call and webcast scheduled for April 3, 2025 at 8:00 A.M. EDT / 2:00 P.M. CEST ...",GlobeNewswire,20250402T201500,"[{'topic': 'Earnings', 'relevance_score': '0.918141'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.495866'}]",Neutral,0.116867,JNJ,"['Business Update', 'Full Year 2024 Financial Results']",Neutral,"Based on the provided headline and summary, the key phrases like 'Business Update' and 'Full Year 2024 Financial Results' suggest important information being shared. However, since the sentiment label is 'Neutral', it indicates that the market may not react strongly to this news, leading to a likely stable or neutral short-term stock movement for JNJ."
Peerage Realty Partners Welcomes New CEO,"TORONTO, April 02, 2025 ( GLOBE NEWSWIRE ) -- Peerage Realty Partners, the prominent leader in luxury residential real estate markets across North America, welcomes Tara Brown to her new role as CEO, Peerage Realty Partners.",Benzinga,20250402T185146,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'Financial Markets', 'relevance_score': '0.161647'}, {'topic': 'Manufacturing', 'relevance_score': '0.5'}]",Bullish,0.415805,JNJ,"['Peerage Realty Partners', 'Welcomes New CEO', 'Tara Brown', 'luxury residential real estate markets', 'prominent leader']",Up,"The appointment of Tara Brown as the new CEO of Peerage Realty Partners, a prominent leader in luxury residential real estate markets, is likely viewed positively by investors. This move signals potential strategic changes or growth opportunities under her leadership, leading to a bullish sentiment and an expected short-term stock movement upwards."
"Will Johnson & Johnson Rally? The Sell-Off May Have Ended - Intra-Cellular Therapies  ( NASDAQ:ITCI ) , Johnson & Johnson  ( NYSE:JNJ ) ","Shares of Johnson & Johnson suffered a significant selloff yesterday The stock found support at a level that had been resistance. Learn how to trade volatility during Q1 earnings season, live with Matt Maley on Wednesday, April 2 at 6 PM ET. Register for free now.",Benzinga,20250402T162656,"[{'topic': 'Earnings', 'relevance_score': '0.310843'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.955357'}]",Neutral,0.073229,JNJ,"['significant selloff', 'support at a level that had been resistance', 'trade volatility', 'Q1 earnings season']",Up,"The evidence suggests that despite the recent selloff, JNJ has found support at a key level, indicating a potential reversal in the stock price. Additionally, the mention of trading volatility during Q1 earnings season could attract investors looking for opportunities, leading to a likely short-term upward movement in JNJ's stock."
Why Investors Need to Take Advantage of These 2 Medical Stocks Now,Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.,Zacks Commentary,20250402T125008,"[{'topic': 'Earnings', 'relevance_score': '0.999682'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.214378'}]",Bullish,0.360791,JNJ,"['Investors looking for ways to find stocks that are set to beat quarterly earnings estimates', 'Zacks Earnings ESP']",Up,"The headline and summary suggest that investors should take advantage of medical stocks, indicating positive sentiment towards the sector. Specifically, the mention of finding stocks set to beat quarterly earnings estimates through Zacks Earnings ESP implies potential positive financial performance for JNJ. Therefore, the likely short-term stock movement for JNJ is 'Up'."
2 Unstoppable Stocks That Could Grow More Than 200% in 10 Years,"Netflix ( NASDAQ: NFLX ) and Intuitive Surgical ( NASDAQ: ISRG ) are leaders in their respective industries, and have produced market-beating returns over long periods. Some might argue that the best is in the rearview mirror for these corporations, considering how well they've performed in the ...",Motley Fool,20250402T094500,"[{'topic': 'Earnings', 'relevance_score': '0.161647'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}]",Somewhat-Bullish,0.254959,JNJ,"['Unstoppable Stocks', 'Could Grow More Than 200%', 'Market-beating returns']",Up,"The sentiment of 'Somewhat-Bullish' combined with phrases like 'Unstoppable Stocks' and 'Could Grow More Than 200%' suggest a positive outlook for JNJ. Investors may interpret this as a signal to expect growth in the stock price, leading to a likely short-term movement upwards."
"Stock Market News For Apr 2, 2025",Wall Street closed mixed on Tuesday to finish the first trading day of second-quarter 2025 after a choppy session.,Zacks Commentary,20250402T081900,"[{'topic': 'Economy - Monetary', 'relevance_score': '0.451494'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.684621'}]",Neutral,-0.009701,JNJ,"['Wall Street closed mixed', 'choppy session']",Neutral,"The evidence suggests that the market sentiment was mixed with a choppy trading session. This uncertainty likely led to a neutral sentiment for JNJ's stock in the short term, as investors may have conflicting views on the company's performance. Without a clear direction from the overall market, JNJ's stock movement is expected to remain neutral."
"NMAX, WTF, JNJ, HIMS, TSLA: Top 5 Trending Stocks Today - Hims & Hers Health  ( NYSE:HIMS ) , Johnson & Johnson  ( NYSE:JNJ ) ","U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07, while the Dow edged down 0.03% to 41,989.96. Market optimism was supported by a 0.7% rise in U.S. construction spending for February.",Benzinga,20250402T022727,"[{'topic': 'Life Sciences', 'relevance_score': '0.5'}, {'topic': 'IPO', 'relevance_score': '0.576289'}, {'topic': 'Financial Markets', 'relevance_score': '0.459462'}, {'topic': 'Manufacturing', 'relevance_score': '0.5'}]",Neutral,0.082659,JNJ,"['U.S. stocks closed higher', 'Market optimism', 'rise in U.S. construction spending']",Up,"The evidence suggests a positive sentiment in the market with U.S. stocks closing higher and market optimism prevailing. Additionally, the rise in U.S. construction spending further supports a positive outlook. Therefore, the likely short-term stock movement for JNJ is 'Up'."
Why Johnson & Johnson Stock Is Sinking Today,"Shares of Johnson & Johnson ( NYSE: JNJ ) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m. ET. The drop comes as the S&P 500 and Nasdaq Composite were down 0.4% and 0.1%, respectively.The healthcare giant was rebuffed by a judge in its latest attempt to settle its yearslong ...",Motley Fool,20250401T183812,"[{'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.108179'}]",Somewhat-Bearish,-0.274999,JNJ,[],Unknown,Failed due to error: Expecting value: line 1 column 1 (char 0)
"Wall Street Inches Up Ahead Of Tariff Day, Tesla Rallies, J&J Tumbles: What's Driving Markets Tuesday? - American Airlines Group  ( NASDAQ:AAL ) ","Wall Street treaded cautiously as Trump's sweeping 20% import tariff plan loomed over $3 trillion in annual goods. Goods producers front-loaded orders, lifting inventories and driving input costs to a three-year high, survey data showed. The 'Trade of the Day' is now live.",Benzinga,20250401T172747,"[{'topic': 'Life Sciences', 'relevance_score': '0.166667'}, {'topic': 'Energy & Transportation', 'relevance_score': '0.166667'}, {'topic': 'Technology', 'relevance_score': '0.166667'}, {'topic': 'Finance', 'relevance_score': '0.166667'}, {'topic': 'Financial Markets', 'relevance_score': '0.650727'}, {'topic': 'Manufacturing', 'relevance_score': '0.166667'}, {'topic': 'Real Estate & Construction', 'relevance_score': '0.166667'}]",Neutral,0.06306,JNJ,"['J&J Tumbles', 'sweeping 20% import tariff plan', 'driving input costs to a three-year high']",Down,"The evidence suggests that J&J is facing challenges as it tumbles amidst the looming import tariff plan and rising input costs. These factors are likely to impact the company's profitability and investor confidence, leading to a predicted short-term stock movement of 'Down'."
Can Johnson & Johnson  ( JNJ )  Keep the Earnings Surprise Streak Alive?,Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,Zacks Commentary,20250401T161011,"[{'topic': 'Earnings', 'relevance_score': '0.999953'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}]",Somewhat-Bullish,0.333937,JNJ,"['impressive earnings surprise history', 'right combination of two key ingredients']",Up,The evidence suggests that Johnson & Johnson has a positive track record of surpassing earnings expectations and currently has the necessary elements for another beat in the upcoming quarterly report. This positive sentiment is likely to drive investor confidence and lead to an increase in JNJ's stock price in the short term.
US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer Claims - Johnson & Johnson  ( NYSE:JNJ ) ,"A U.S. bankruptcy court rejected J&J subsidiary Red River Talc's prepackaged bankruptcy plan. J&J will litigate talc lawsuits instead of settling, reversing $7 billion in legal reserves and challenging plaintiff claims in court.",Benzinga,20250401T135117,"[{'topic': 'Earnings', 'relevance_score': '0.158519'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.161647'}]",Somewhat-Bearish,-0.221286,JNJ,"['US Judge Rejects', ""J&J subsidiary Red River Talc's prepackaged bankruptcy plan"", 'litigate talc lawsuits instead of settling', 'reversing $7 billion in legal reserves', 'challenging plaintiff claims in court']",Down,"The news of the U.S. bankruptcy court rejecting J&J's subsidiary's bankruptcy plan and deciding to litigate talc lawsuits instead of settling indicates a challenging legal battle ahead. Reversing $7 billion in legal reserves suggests potential financial implications. This uncertainty and legal pressure are likely to create a negative sentiment among investors, leading to a short-term downward movement in JNJ stock."
"This Recession-Proof Stock Soared Through the Dot-Com Bust, the Financial Crisis, and the 2022 Inflation Spike. Is It a No-Brainer Buy for the Trump Tariff Era?","President Donald Trump has barely been in office for two months, but his policies and proposals have already rocked the stock market.The S&P 500 slipped into a brief correction in March, and the Nasdaq Composite remains there today.",Motley Fool,20250401T134500,"[{'topic': 'Economy - Monetary', 'relevance_score': '0.158519'}, {'topic': 'Life Sciences', 'relevance_score': '0.333333'}, {'topic': 'Retail & Wholesale', 'relevance_score': '0.333333'}, {'topic': 'Financial Markets', 'relevance_score': '0.999612'}, {'topic': 'Manufacturing', 'relevance_score': '0.333333'}, {'topic': 'Earnings', 'relevance_score': '0.310843'}]",Neutral,0.072983,JNJ,[],Unknown,Failed due to error: Expecting value: line 1 column 1 (char 0)
J&J's Third Bankruptcy Attempt to End Talc Suits Rejected,J&J fails in its third attempt to settle tens of thousands of lawsuits claiming its talc-based powder caused cancer.,Zacks Commentary,20250401T133000,"[{'topic': 'Earnings', 'relevance_score': '0.682689'}, {'topic': 'Life Sciences', 'relevance_score': '1.0'}, {'topic': 'Financial Markets', 'relevance_score': '0.214378'}]",Neutral,-0.113917,JNJ,"[""J&J's Third Bankruptcy Attempt"", 'End Talc Suits Rejected', 'fails in its third attempt', 'tens of thousands of lawsuits', 'talc-based powder caused cancer']",Down,"The news of J&J's third bankruptcy attempt being rejected and failing to settle tens of thousands of lawsuits is likely to have a negative impact on investor confidence. The ongoing legal battles and the association of talc-based powder with cancer create uncertainty around the company's future liabilities, leading to a potential decrease in stock value in the short term."
